Journal of Nuclear Medicine Technology, Vol 26, Issue 3 155-163, Copyright © 1998 by Society of Nuclear Medicine

ARTICLES

Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging

PJ Bohdiewicz
Nuclear Medicine Department, William Beaumont Hospital, Royal Oak, MI 48073-6769, USA.

OBJECTIVE: Colon cancer is the second most common cause of cancer mortality. Ovarian cancer is the most common gynecologic malignancy cause of death in women. A labeled monoclonal antibody attaches to a tumor-associated antigen and allows these tumor masses to be imaged or treated, depending on the radionuclide used. Indium-111 satumomab pendetide was the first labeled monoclonal antibody to be approved by the Food and Drug Administration (FDA) for tumor imaging. It is reactive with most colorectal and ovarian cancers, as well as other cancers. After reading this article, the technologist will understand the FDA approval process, phase trial results, safety and adverse reactions, human antimurine antibody response, indications, imaging protocol, and strengths and weaknesses of imaging with satumomab pendetide. Representative cases are presented.

This article has been cited by other articles:

				M. Jain, S. C. Chauhan, A. P. Singh, G. Venkatraman, D. Colcher, and S. K. Batra Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors Cancer Res., September 1, 2005; 65(17): 7840 - 7846. [Abstract] [Full Text] [PDF]

				J. Y. C. Wong, D. Z. Chu, L. E. Williams, D. M. Yamauchi, D. N. Ikle, C. S. Kwok, A. Liu, S. Wilczynski, D. Colcher, P. J. Yazaki, et al. Pilot Trial Evaluating an 123I-Labeled 80-Kilodalton Engineered Anticarcinoembryonic Antigen Antibody Fragment (cT84.66 Minibody) in Patients with Colorectal Cancer Clin. Cancer Res., August 1, 2004; 10(15): 5014 - 5021. [Abstract] [Full Text] [PDF]